A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 TO 64 YEARS OF AGE WITH INCREASED RISK FOR PNEUMOCOCCAL DISEASE

Registry ID

V116-008

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2023-02-09

Last update

2022-12-16

Conditions

• PNEUMOCOCCAL DISEASE

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN CHILDREN AND ADOLESCENTS WITH INCREASED RISK OF PNEUMOCOCCAL DISEASE
• A PHASE 2 MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A 25-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY PCV-NAÏVE ADULTS
• A PHASE 3 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY,AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-EXPERIENCED ADULTS 50 YEARS OF AGE OR OLDER
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V114 IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER (PNEU-AGE)
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF V114 IN HEALTHY INFANTS (PNEU-LINK)/ PROTOCOL 031-00

View on source registry